November 20, 2006 -- Somaxon touted positive data on its non-narcotic sedative candidate, Silenor; CoTherix will be bought by Actelion of Switzerland for $13.50 per share; Neopharm said cintredekin besudotox proved safe in newly diagnosed brain cancer patients; BioCryst received Orphan Designation for Fodosine, a treatment for leukemia; MGI Pharma reported positive interim results for Gliadel Wafer for malignant glioma; Johnson & Johnson released positive data for Procrit on a less frequent regimen; and Introgen said preclinical work with NPRL2 nanoparticles produced a 90% inhibition of tumor growth in lung cancer. The Centient Biotech 200™ dropped 3 points to 4006, a loss of .08%. More details...
